Introduction
While the risk of stroke associated with atrial fibrillation (AF) is wellrecognized, this common arrhythmia also independently increases the risk of all-cause mortality. 1, 2 Recent several studies focused on increased risk of death and its specific causes in both randomized control trials (RCTs) [3] [4] [5] [6] and real-world cohorts among patient with AF. [7] [8] [9] In general, stroke-related death accounted for only 7-10% of all-cause mortality despite the high risk for stroke. 10 Importantly, causes of death and their incidences vary substantially across study designs, 11 regions, 12 and periods at enrolment of patients. 13 Those with AF in routine clinical practice often have several cardiovascular (CV) risk factors and other non-CV co-morbidities, all of which may contribute to an increased mortality, especially amongst the elderly. 14 However, there are limited data on the proportions of specific causes of death across age groups and the indicators of both CV and non-CV deaths, especially in Asian cohorts where the burden of AF is greatly increasing. 15 The objective of this analysis was to describe cause-specific death between age groups and to identify factors associated with all-cause, CV, and non-CV mortality using data from the Fushimi AF Registry; a community-based cohort of Japanese AF patients.
Methods
The detailed study design, patient enrolment, the definition of the measurements, and subjects' baseline clinical characteristics of the Fushimi AF Registry were previously described (UMIN Clinical Trials Registry: UMIN000005834). 16, 17 The inclusion criterion for the registry is the documentation of AF on a 12-lead electrocardiogram or Holter monitoring at any time. There were no exclusion criteria. A total of 80 institutions participated in the registry of Fushimi district, Kyoto, Japan. We started to enroll patients from March 2011. Collection of follow-up information was mainly conducted through review of the inpatient and outpatient medical records, and additional follow-up information was collected through contact with patients, relatives and/or referring physicians by mail or telephone. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethical committees of the National Hospital Organization Kyoto Medical Center and Ijinkai Takeda General Hospital.
Group assignment and definition
Baseline characteristics at the entry into the registry were described in this overall population and compared between the patients alive at the end of the follow-up and those who died during the follow-up. We also compared baseline characteristics and clinical outcomes among the three groups by age (< _74 years, 75-84 years, and > _85 years), as previously reported. 14 The risk of stroke was assessed by the CHADS 2 18 score and CHA 2 DS 2 -VASc score. 19 The type of AF was classified into two groups;
paroxysmal AF and sustained AF, which was defined as the combination of persistent AF and permanent AF. 20 Anaemia was defined according to the World Health Organization criteria (haemoglobin level <13.0 g/dL in men and <12.0 g/dL in women). Renal dysfunction was diagnosed as the estimated glomerular filtration rate <60 mL/min/m 2 at baseline. Oral anticoagulant (OAC) included warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban. Anti-platelet drug (APD) included aspirin, clopidogrel, ticlopidine, and cilostazol. OAC and APD usage were based on the prescription data at enrolment.
Study endpoints
The primary endpoint in the analysis was all-cause death, and its specific cause(s) during the follow-up period. Causes of death were adjudicated after consideration of all the available information and were classified according to the following pre-specified groups: CV, non-CV, as well as undetermined death when the quality of the information could not allow the investigators to appropriately identify cause of death. CV deaths were further subclassified as cardiac (heart failure, acute coronary syndrome, or dysrhythmia), vascular (ischaemic stroke, systemic embolism, haemorrhagic stroke, other intracranial haemorrhage such as epidural/subdural haematoma or extracranial bleeding), and others (which included other vascular causes and those vascular deaths with insufficient information to definitively assign a subclassification). Non-CV deaths included those resulting from malignancy, respiratory failure, infection/sepsis, renal failure, and others.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation, or median and interquartile range according to the distributions and compared using Student's t-test or Wilcoxon rank-sum test on the basis of the distribution. Categorical variables are presented as numbers and percentages and compared using the v 2 test when appropriate; otherwise, we used Fisher's exact test. The cumulative incidences of clinical outcomes were estimated by the Kaplan-Meier method, and differences were assessed with the log-rank test.
We carried out multivariate analysis for the indicators of all-cause death, CV death, and non-CV death using the Cox proportional hazards model. The covariates chosen to be included were age (per 10 years), female (vs. male), body mass index as the three categorical variable (<18.5 kg/m , sustained AF (vs. paroxysmal AF), pre-existing heart failure, hypertension, diabetes mellitus, previous stroke or transient ischaemic attack (TIA), peripheral artery disease (PAD), prior myocardial infarction, anaemia, chronic obstructive pulmonary disease (COPD), renal dysfunction, dyslipidaemia, previous major bleeding, prescription of renin-angiotensin system inhibitor, each prescription of b-blocker, APD, OAC, diuretics, digitalis, and statin at baseline. We used JMP version 12 (SAS Institute, Cary, NC, USA) to perform all of these analyses. Two-sided P-values less than 0.05 were considered statistically significant.
Results
Of 4441 patients who were enrolled by the end of November 2015, follow-up data (collected annually) were available for 4066 patients (91.6%) as of November 2016. Of these 4066 patients, 21 patients were excluded because their baseline prescription data were unavailable at baseline. Finally, a total of 4045 patients at baseline were included in the current analysis.
During the median follow-up of 1105 (interquartile range 669-1825) days, a total of 705 patients (17.4%) died. These patients were older than 3340 patients who were alive at the end of follow-up and had higher prevalence of various co-morbidities such as previous stroke/TIA and pre-existing heart failure with higher CHA 2 DS 2 -VASc score ( Table 1) . Table 2 shows the causes of death in the entire study population. CV causes accounted for 25.5% of all-cause deaths; heart failure; 16.3%, ischaemic stroke; 4.8%, and haemorrhagic stroke; 1.7%. Non-CV causes consisted of a substantial proportion (54.6%) including malignancy; 23.1% and infection/sepsis; 17.3%. Causes of death were not determined in 20.4% of patients who died during the follow-up. As shown in Figure 1 , the event rate of all-cause, non-CV, and cardiac death, and death due to stroke were 5.5, 3.1, 0.9, and 0.4 per 100 person-years during the follow-up, respectively. Table 3 shows the comparison of baseline characteristics and comorbidities among age subgroups (< _74 years, 75-84 years, and > _85 years). With higher ages, greater prevalence of co-morbidities became evident, especially previous stroke/TIA, pre-existing heart failure, renal dysfunction, and anaemia.
The proportions of specific causes of death between the three age subgroups at baseline are shown in ; NOAC, non-vitamin K oral anticoagulant. Categorical data are presented as n (%). Continuous data are presented as mean ± standard deviation (SD), or median and interquartile range (25-75%) according to the distribution. of cardiac and intracranial deaths between the three groups. The proportion of each cause of non-CV death varied substantially by age subgroup, with an increasing proportion of infection-related death and deaths of undetermined cause with age strata.
Mortalities of specific causes of death increased in accordance with age strata ( Figure 3A) . Unadjusted hazard ratios (HRs) for cardiac death were 2.16 [95% confidence interval (CI) 1.38-3.44] at age 75-84 years, and 5.83 (95% CI 3.62-9.44) at age > _85 years, compared with those aged < _74 years ( Figure 3B ). With regard to non-CV death, those due to infection were higher in accordance with aging. Deaths of undetermined cause were also higher as age increased.
On multivariate Cox regression analysis, baseline variables associated with a highest risk of all-cause death were anaemia (HR 2.52, 95% CI 2.10-3.02) (Figure 4) , followed by PAD, previous stroke/TIA, older age (per 10 years increase), pre-existing heart failure, COPD, prescription of digitalis, and renal dysfunction. Female gender, OAC prescription and that of statin was associated with a significantly lower risk of all-cause death. As shown in Figure 5 , the strongest indicators for higher risk of CV death was pre-existing heart failure (HR 2.42, 95% CI 1.66-3.54) and that of non-CV death was anaemia (HR 2.84, 95% CI 2.22-3.65). Some differences between CV and non-CV deaths existed in the predictive values of clinical factors. The prescription of OAC at baseline was significantly associated with a lower incidence of non-CV death, but not with that of CV death.
There was a higher prevalence of the CV co-morbidities such as pre-existing heart failure, previous stroke/TIA in patients with OAC at baseline (Supplementary material online, Table S1 ). The cumulative incidence of non-CV death was higher in patients with OAC than in those without, although there was no significant difference in CV death (Supplementary material online, Figure S1 ), due to the differences in mortality due to malignancy and infection (Supplementary material online, Figure S2 ).
Discussion
The principal findings of this study in a Japanese community-based AF cohort were as follows: (i) the most common cause of CV death was not stroke-related, but that of heart failure, which was one of major causes of death next to malignancy and infection; (ii) the mortality due to infection and undetermined cause increased substantially in accordance with age; and (iii) CV death was most strongly associated with pre-existing heart failure and non-CV death was with anaemia. There were some differences about clinical indicators for CV and non-CV deaths.
Causes of death in AF patients
Cardiac death, mainly heart failure, was the most common CV death in the present study, in agreement with the findings in both RCTs [3] [4] [5] [6] and real-world cohorts. [7] [8] [9] Meanwhile, the mortality due to stroke accounted for 6.5% of all-cause deaths (0.4 per 100 person-years). This proportion was also comparable with those in the prior published reports. [3] [4] [5] [6] [7] [8] [9] On the contrary, non-CV death varied across their study designs and populations. Indeed, the proportion of non-CV cause among all-cause death was 29.7% in the meta-analysis of four RCTs of non-vitamin K oral anticoagulants. 3 By comparison, there was higher proportion of non-CV death in real-world cohorts such as 35.8% in the international GARFIELD-AF registry, 7 42.7% in a
French regional registry, 8 and 66.0% in a French nationwide database. 9 In the present study, non-CV deaths, mainly due to malignancy and infection/sepsis, accounted for more than half (54%) of all-cause deaths. These differences perhaps reflect the higher prevalence of In the present study, deaths of undetermined cause occurred in 20.4%, which was comparable with that in the GARFIELD-AF registry (23.7%). 7 Causes of death cannot be determined definitely in a certain proportion of patients in the routine clinical practice. As for the proportions among specific causes of death between three age groups, the total proportion of CV causes of death were almost identical between each of three age groups. Meanwhile, some differences across age groups exists for non-CV causes, for example, the proportion of death due to infection/sepsis and undetermined cause increased with age strata.
Factors associated with death
Anaemia is a component of several algorithms that are used to determine the individual risk of bleeding in these patients. [21] [22] [23] Moreover, a recent sub-analysis of a RCT showed a strong association of anaemia Figure 4 Indicators of all-cause death. Data are presented hazard ratio and 95% confidence interval. Hazard ratio were adjusted by age, female, body mass index, sustained atrial fibrillation (vs. paroxysmal atrial fibrillation), pre-existing heart failure, hypertension, diabetes mellitus, previous stroke or transient ischaemic attack, peripheral artery disease, prior myocardial infarction, anaemia, chronic obstructive pulmonary disease, renal dysfunction, dyslipidaemia, previous major bleeding, prescription of renin-angiotensin system inhibitor, each prescription of b-blocker, anti-platelet drug, oral anticoagulants, diuretics, digitalis, and statin at baseline. AF, atrial fibrillation; TIA, transient ischaemic attack; PAD, peripheral artery disease; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; OAC, oral anticoagulant. not only with bleeding but also all-cause mortality in patient with AF receiving OAC, irrespective of warfarin or apixaban use. 24 The present study in a real-world cohort also demonstrated that anaemia was strongly associated with both CV and non-CV mortality in AF patients. While not specifically examined in this study, multiple possible mechanisms may exist for the association between anaemia and death; occult bleeding, general vascular frailty, renal dysfunction, nutrition status, and aging per se. Pre-existing heart failure was identified as a strong indicator of allcause death and CV death, not non-CV death in the present study, consistent with the sub-analysis from the RE-LY trial. 4 Optimal management of heart failure as well as optimal antithrombotic therapy again appears to be the cornerstone for improving survival in patients with AF. In the present study, the prescription of OAC was associated with a lower incidence of all-cause death, mainly due to the lower incidence of non-CV death. Patients not using OAC may also have had various comorbidities with poor general clinical condition, and may have been considered unsuitable for OAC use.
Study limitations
The results of the present study have several limitations. First, the results were derived from a prospective observational study; therefore, it only shows association and not causality with the limitations inherent to the design such as selection bias and unmeasured confounders. Since the present study was conducted in an urban district in Japan, the results cannot be easily extrapolated to other rural areas or countries. Second, the statistical analysis was based only on clinical details at the time of enrolment. Thus, changes of clinical backgrounds and treatments including prescriptions were not taken into consideration during the follow-up periods. Third, quality of anticoagulation with time in therapeutic rage by warfarin and OAC adherence were also not investigated during the follow-up. Fourth, the percentage of deaths due to undetermined cause among all-cause death was substantially large (20.4%), especially with increasing rates in the elderly, which may result in underestimation of the incidence of each specified cause of death such as stroke or other CV causes. However, cause of death is sometimes difficult to determine, even in prospective randomized trials with close and strict data monitors. Especially, elderly patients are unlikely to be given full examination to pinpoint the cause of death in routine clinical practice. There is a wide variety in the proportion of undetermined causes in observational studies: 20.5% in the present study, compared with 3.2%, 8 none, 9 and 23.7%. 7 Unlike uniform medical information from retrospective analyses in a single centre 8 and from nationwide database in hospitalized AF patients, 9 large-scale multi-institutional observational registries such as ours and the GARFIELD registry 7 show higher percentage of undermined cause, probably due to heterogeneities in the quality of medical information across the participating institutions. Fifth, deaths recorded due to infection/sepsis, which increased with aging, might also have occurred as a consequence from the preceding CV event such as stroke or heart failure in the elderly AF patients. Sixth, there was no adjudication committee for outcome events. Finally, we did not have a control group (patients without AF) that would have allowed us to compare the distribution and predictors of each of the specific causes of mortality in patients with AF.
Conclusions
In a community-based Japanese AF cohort, CV deaths were not mainly related to stroke but to heart failure, irrespective of age groups. Non-CV deaths, especially death due to infection/sepsis, varied with different age strata. Clinical factors that were associated with CV and non-CV death were distinct. These findings provide important insights into the development of effective targeted interventions and reducing overall mortality in an increasing population with associated AF.
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